Here are 1-2 brief analogies to describe Qiagen:

• Intel for molecular biology labs
• Qualcomm for genetic testing and research

• Sample Preparation Kits & Instruments: Solutions for isolating, stabilizing, and purifying DNA, RNA, and proteins from various biological samples, including both manual kits and automated systems like QIAcube and QIA symphony.
• Molecular Diagnostic Systems (MDx): Integrated platforms and assays for detecting pathogens or biomarkers in clinical samples, exemplified by the QIAstat-Dx system for syndromic testing and QuantiFERON-TB Gold Plus for tuberculosis.
• Next-Generation Sequencing (NGS) Solutions: Comprehensive workflows including library preparation kits, target enrichment panels, and instruments for high-throughput DNA sequencing.
• PCR and Real-Time PCR Assays: Kits and reagents for polymerase chain reaction (PCR) and quantitative real-time PCR, used for gene expression analysis, genotyping, and pathogen detection.
• Bioinformatics Software: Tools and knowledge bases for analyzing, interpreting, and managing genomic and proteomic data generated by their molecular technologies.

Qiagen (QGEN) primarily sells its innovative products and solutions to other companies and institutions globally, rather than directly to individuals. Due to its highly diversified customer base spanning numerous markets and geographies, Qiagen does not typically have individual "major customers" (specific named companies) that account for a significant portion of its revenue (e.g., 10% or more), and as such, these are not disclosed in its public filings. Instead, its customer base can be categorized into the following primary segments:

• Clinical Diagnostics & Healthcare Providers: This category includes hospitals, clinical reference laboratories (e.g., those performing routine or specialized diagnostic tests), and public health institutions. These customers utilize Qiagen's molecular diagnostic solutions for infectious disease testing, oncology, human identification, and other clinical applications. Examples of such entities, though not individually major customers, include large hospital networks and independent diagnostic lab corporations.
• Pharmaceutical & Biotechnology Companies: These customers are involved in drug discovery, development, clinical trials, and manufacturing quality control. They use Qiagen's sample and assay technologies for research and development (R&D) purposes, biomarker discovery, and ensuring the safety and efficacy of their products. This segment includes both large multinational pharmaceutical firms and smaller, innovative biotechnology companies.
• Academic & Research Institutions: This segment comprises universities, government-funded research centers (e.g., those under the National Institutes of Health or similar international bodies), and non-profit research organizations. Researchers within these institutions employ Qiagen's products for fundamental life science research, genomics, proteomics, and other scientific investigations.

Thierry Bernard, Chief Executive Officer

Thierry Bernard joined QIAGEN in February 2015 and was named Chief Executive Officer in March 2020 after serving in an interim capacity. Prior to joining QIAGEN, Mr. Bernard spent 15 years at bioMérieux SA, where he held roles of increasing responsibility, including Corporate Vice President, Global Commercial Operations, Investor Relations, and the Greater China Region. He also held senior management positions at several other international companies before bioMérieux. Mr. Bernard has served on the Board of Directors of T2 BioSystems since 2020, was named Chair of the AdvaMedDx Board of Directors in March 2023, and joined the Board of Directors of Neogen Corporation (NASDAQ: NEOG) in 2024. He holds degrees and certifications from institutions including Sciences Po, the London School of Economics, the College of Europe, and Harvard Business School.

Roland Sackers, Chief Financial Officer

Roland Sackers joined QIAGEN in 1999 as Vice President Finance and has served as Chief Financial Officer since 2004. He became a member of the Managing Board in 2006. From 1995 to 1999, Mr. Sackers worked as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. He earned his Masters Degree in Business Administration (Diplom-Kaufmann) from the University of Münster, Germany. Mr. Sackers has been a member of the Supervisory Board and Chairman of the Audit Committee of Evotec SE since 2019. He is also a board member of the industry association BIO Deutschland and previously served as a member of the Supervisory Board and Audit Committee of IBS AG, and on the board of directors of Operon Biotechnologies, Inc.. From 2011 to 2018, he was a non-executive director and chair of the audit committee of Immunodiagnostic Systems Holding PLC (IDS).

Fernando Beils, Senior Vice President, Head of Global Commercial Operations

Fernando Beils is the Senior Vice President, Head of Global Commercial Operations at QIAGEN.

Stephany Foster, Senior Vice President, Head of Human Resources

Stephany Foster is the Senior Vice President, Head of Human Resources at QIAGEN, a role she assumed in October 2019. Before joining QIAGEN in 2005 as Head of Global Internal Audit, she worked in internal audit at Morgan Franklin and Independence Air. Ms. Foster began her career at PricewaterhouseCoopers, specializing in Sarbanes Oxley Auditing. She holds a master's degree in Accounting from the University of Notre Dame and is a Certified Public Accountant (CPA), a Certified Internal and Information Systems Auditor (CIA/CISA), and a Certified Fraud Examiner (CFE).

Antonio Santos, Senior Vice President, Head of Global Operations

Antonio Santos serves as the Senior Vice President, Head of Global Operations for QIAGEN.

Key risks to Qiagen's business include intense competition and rapid technological advancements, fluctuating demand influenced by economic conditions and customer budgets, and operational challenges including regulatory compliance and managing international operations.

• Competition and Rapid Technological Advancements: Qiagen operates in the highly dynamic molecular diagnostics and life science research industry, facing significant competition from both established companies like Roche and Illumina, as well as emerging players, particularly in the Asia-Pacific region. This competitive landscape is constantly reshaped by rapid technological innovations in areas such as next-generation sequencing (NGS), liquid biopsy, and automation. The company must continuously innovate and protect its product differentiation to maintain its market position against rivals.
• Fluctuating Demand and Economic Conditions: Qiagen's business is susceptible to variations in demand for its products, which can be influenced by broader economic conditions, customer budgets, and funding cycles in research and academic markets. For instance, cautious capital spending by some life sciences customers has been observed. Additionally, geopolitical factors like U.S.-China tariffs can impact profitability and create financial headwinds.
• Regulatory and Operational Challenges: The company faces ongoing challenges related to obtaining and maintaining regulatory approvals for its products, such as those required by IVDR. Furthermore, managing international operations, which involves navigating currency fluctuations, diverse regulatory processes, and logistical complexities, presents a continuous risk. Successful integration of acquisitions and adapting products into integrated solutions are also critical operational considerations.

Qiagen (symbol: QGEN) operates within several significant addressable markets for its main products and services. The company's total addressable market was estimated at approximately $11 billion in 2024, with a projection to grow to between $13 billion and $14 billion by 2028 globally.

Here's a breakdown of the addressable markets for Qiagen's key offerings:

• Molecular Diagnostics: The global molecular diagnostics market was valued at approximately $14 billion in 2024 and is projected to reach $30.4 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 9% from 2025 to 2033. North America held the largest share of this market, accounting for 40.95% in 2024. Another estimate places the global market at $15.26 billion in 2024, expanding to $21.21 billion by 2032 with a CAGR of 4.2% from 2025-2032.
• PCR Technologies (including QIAcuity Digital PCR, NeuMoDx, QIAstat-Dx): The global PCR technologies market size was approximately $15.78 billion in 2024 and is predicted to increase to $31.39 billion by 2034, with a CAGR of 7.12% from 2025 to 2034. The U.S. market for PCR technologies alone was valued at $5.49 billion in 2024 and is projected to reach $11.10 billion by 2034. More specifically, the global digital PCR (dPCR) market is estimated at $9.39 billion in 2025 and is poised to reach $23.15 billion by 2035, exhibiting a CAGR of 9.4% during the forecast period.
• Next-Generation Sequencing (NGS) Solutions: The global next-generation sequencing market was valued at $9.85 billion in 2024 and is projected to reach $56.04 billion by 2033, demonstrating a substantial CAGR of 21.31% from 2025 to 2033. Another source estimates the global NGS market size at $23.3 billion in 2024, with a projection to reach $85.4 billion by 2033 at a CAGR of 15.5%. North America held the largest market share in NGS in 2024, at over 39.7%.
• Sample Technologies: While a specific global market size for "sample technologies" as a standalone category is not provided, it is a core component of molecular testing and an area where Qiagen is a leader. These technologies are foundational to molecular diagnostics and next-generation sequencing workflows.
• QuantiFERON: This is a key product for detecting latent tuberculosis infection. A specific global market size for QuantiFERON or latent TB testing within the broader molecular diagnostics market was not separately identified.
• Bioinformatics (QIAGEN Digital Insights): While Qiagen has significant offerings in bioinformatics, a distinct global addressable market size specifically for "bioinformatics solutions" for molecular testing or life sciences was not identified in the provided search results.

For QuantiFERON and Bioinformatics, specific addressable market sizes directly corresponding to these individual products/services were not explicitly available in the provided information.

• Launch of New Automated Sample Preparation Instruments: Qiagen plans to introduce three new automated sample preparation instruments between 2025 and 2026. The QIAsymphony Connect, the next generation of its flagship platform, is undergoing a phased launch starting in 2025 with a full commercial release in mid-2026. It is designed for liquid biopsy, oncology, and genomics workflows with enhanced automation and digital connectivity. Additionally, QIAsprint Connect, slated for a 2026 launch, will mark Qiagen's entry into the high-throughput automation market, while QIAmini, also expected in 2026, will offer cost-effective automation for smaller laboratories.
• Expansion in Digital PCR and New Assays: The company is significantly expanding its QIAcuity digital PCR platform, aiming for U.S. regulatory clearance for the QIAcuity-Dx version in 2024 for clinical use, with a BCR-ABL biomarker assay submission planned for 2025. Over 100 new assays are being launched, supported by a more than tripling of sales specialists to drive adoption.
• Acquisition of Parse Biosciences and Entry into the Single-Cell Market: The acquisition of Parse Biosciences, expected to be completed in late 2025, provides Qiagen with entry into the rapidly growing single-cell market. Parse Biosciences offers scalable, instrument-free solutions for single-cell research, which is projected to contribute approximately $40 million in sales to Qiagen in 2026, with strong double-digit growth in subsequent years. This move is also anticipated to accelerate growth in Qiagen Digital Insights (QDI) bioinformatics business.
• Sustained Performance of Core Diagnostic Products: Key existing diagnostic products like QuantiFERON and QIAstat-Dx are expected to maintain strong growth. QuantiFERON is projected for at least 10% constant exchange rate (CER) growth in 2024 and double-digit growth in 2025, driven by global market adoption. QIAstat-Dx has shown dynamic double-digit growth, including a 40% CER pace in Q3 2024, supported by the launch of a new gastrointestinal panel in the U.S.
• Operational Efficiencies and Portfolio Rationalization: While not a direct revenue driver, Qiagen's focus on operational efficiencies and strategic portfolio decisions, such as the discontinuation of the NeuMoDx system by 2025, are contributing to improved profitability and freeing up resources for investment in growth areas. The company aims to improve its adjusted operating income margin by at least 150 basis points to above 30% in 2025 and well above 31% by 2028.

Share Repurchases

• QIAGEN announced a plan to complete a $500 million synthetic share repurchase in early January 2026, which would bring total shareholder returns to over $1 billion since 2024, ahead of its 2028 goal.
• Shareholders approved a resolution in June 2024 to implement a share repurchase of up to $300 million, designed to return cash more efficiently and enhance earnings per share.

Share Issuance

• In August 2025, QIAGEN announced an offering of $750 million in senior, unsecured net share settled convertible bonds due 2032.
• The shares underlying these convertible bonds represent approximately 11.2 million shares, or about 5.1% of the company's current issued and outstanding share capital.
• QIAGEN's shares outstanding increased by 3.08% in 2023 to 0.231 billion from 2022, and then declined by 2.56% in 2024 to 0.225 billion from 2023.

Inbound Investments

• In March 2020, Thermo Fisher Scientific proposed to acquire QIAGEN for €39 per share in cash, valuing the transaction at approximately $11.5 billion, including assumed debt; however, the offer was terminated in August 2020 as it did not meet the required shareholder approval threshold.
• Fivespan Partners, an activist investment firm, acquired a stake in Qiagen in April 2025, potentially indicating strategic discussions aimed at influencing management decisions and increasing shareholder value.

Outbound Investments

• In November 2025, QIAGEN entered into a definitive agreement to acquire Parse Biosciences for an upfront cash payment of approximately $225 million, with potential additional milestone payments of up to $55 million, to expand its Sample technologies portfolio into the single-cell sequencing market.
• QIAGEN announced its intention to acquire Verogen for $150 million in January 2023, which included the acquisition of GEDmatch, a genetic genealogy service.
• In May 2022, QIAGEN acquired a majority stake in BLIRT S.A., enhancing its R&D and manufacturing capabilities for recombinant enzymes and molecular biology reagents.

Capital Expenditures

• QIAGEN focuses its capital expenditures on strategic initiatives to accelerate growth in key areas such as QIAcuity digital PCR (dPCR), QIAstat-Dx syndromic testing, and its QIAGEN Digital Insights (QDI) portfolio.
• Capital expenditures are also directed towards production capacity expansion initiatives, supporting its five pillars of growth.